KK Gynaecological Cancer Centre
The mission of the KK Gynaecological Cancer Centre (GCC) is to provide an excellent, efficient and compassionate service to our patients through better care made possible with the highest ethical standards and professionalism.
KK GCC is the only centre in Singapore and Asia to participate in the HPV Vaccine Trial - FUTURE II Study. This is a worldwide trial on a vaccine to protect women against the human papilloma virus (HPV), which causes cervical cancer.
Cancer of the Cervix
In its earliest stages, cervical cancers are highly curable. Early detection is therefore the key to improving survival.
Here at KKH, our five-year survival rate for Cervix cancer is:
| Stage |
Percentage |
| Stage 1a |
98% |
| Stage 1b |
84% |
| Stage 2a |
71% |
| Stage 2b |
50% |
Cancer of the Uterus
Cancer of the uterus is the third commonest cancer of the female genital tract in Singapore. It usually affects the endometrium (lining of the uterus). If treated early, the cure rate is very good.
Here at KKH, our five-year survival rate for Uterus cancer is:
| Stage |
Percentage |
| Stage 1 |
92% |
| Stage 2 |
90% |
Ovarian Cancer
Epithelia cell cancers of the ovary are more common than germ cell cancers. Names of different types of epithelia ovarian cancers include mucinous or serous cystadenocarcinoma, clear cell carcinoma and endometrioid carcinoma of the ovary.
For very early stage disease and non-aggressive types, further treatment may not be required. For the more advance and aggressive types of cancers, often chemotherapy is the treatment of choice.
Here at KKH, our five-year survival rate for Ovarian cancer is:
| Stage |
Percentage |
| Stage 1 |
90% |
| Stage 2 |
55% |